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Abstract
Background: Renal kallikrein (KLK1) synthesis and urinary excretion are reportedly diminished during AKI (acute
kidney injury) in animal models, and provision of kallikrein abrogates renal injury in this setting, but data in human
AKI is limited. Therefore we first examined KLK1 renal excretion in human AKI, and then probed potential
endocrine and epigenetic mechanisms for its alterations.
Methods: KLK1 enzymatic activity excretion was evaluated in urine from patients with established or incipient AKI,
versus healthy/non-hospital as well as ICU controls. Endocrine control of KLK1 excretion was then probed by
catecholamine and aldosterone measurements in established AKI versus healthy controls. To examine epigenetic
control of KLK1 synthesis, we tested blood and urine DNA for changes in promoter CpG methylation of the KLK1
gene, as well as LINE-1 elements, by bisulfite sequencing.
Results: Patients with early/incipient AKI displayed a modest reduction of KLK1 excretion, but unexpectedly,
established AKI displayed substantially elevated urine KLK1 excretion, ~11-fold higher than healthy controls, and ~3-
fold greater than ICU controls. We then probed potential mechanisms of the change. Established AKI patients had
lower SBP, higher heart rate, and higher epinephrine excretion than healthy controls, though aldosterone excretion
was not different. Promoter KLK1 CpG methylation was higher in blood than urine DNA, while KLK1 methylation in
blood DNA was significantly higher in established AKI than healthy controls, though KLK1 methylation in urine
tended to be higher in AKI, directionally consistent with earlier/incipient but not later/established changes in KLK1
excretion in AKI. On multivariate ANOVA, AKI displayed coordinate changes in KLK1 excretion and promoter
methylation, though directionally opposite to expectation. Control (LINE-1 repetitive element) methylation in blood
and urine DNA was similar between AKI and controls.
Conclusions: Unexpectedly, increased KLK1 excretion in AKI patients was found; this increase is likely to be due in
part to increments in adrenergic tone during BP depression. Epigenetic changes at KLK1 may also play a role in
early changes of KLK1 expression and thus AKI susceptibility or recovery.
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Background
The incidence of acute kidney injury (AKI) in hospitalized
patients is estimated to be 5-10%, and is much higher in
the critically ill [1,2]. Despite the potential for recovery of
kidney function, acute kidney injury is associated with sub-
stantial morbidity and even mortality. AKI, due to ische-
mia or nephrotoxic agent exposure, may lead to death or
sublethal injury of proximal tubular cells, after which sur-
viving cells may repolarize and/or de-differentiate, prolifer-
ate, migrate to denuded areas, re-differentiate, and restore
nephron structure (including the tubular epithelium) and
function [3,4].
The serine protease kallikrein (KLK1; E.C.-3.4.21.35;
OMIM 147910), excreted from kidney into urine, catalyzes
the cleavage of low molecular weight kininogen to lysyl-
bradykinin (kallidin), which exhibits both vasodilator and
natriuretic pharmacological properties in the kidney; if
these properties occur in vivo, the potential of the system
for regulating blood pressure is clear [5].
Renal kallikrein levels were markedly reduced in an ami-
noglycoside-induced AKI animal model [6], and KLK1
gene transfer protected against aminoglycoside-induced
nephropathy by diminishing apoptosis and inflammation
[7]. In addition, KLK1 infusion during aminoglycoside
treatment attenuated drug-induced renal dysfunction, cor-
tical damage, and apoptosis in the rat [8]. Previously, we
have reported that urinary KLK1 excretion was diminished
in renal allograft recipients with a clinical diagnosis of
acute tubular necrosis (ATN) [9]; since urinary KLK1 ori-
ginates in the kidney, reduced urinary kallikrein levels may
reflect impaired renal function. However, this finding has
not been pursued in humans.
In mammals, cytosine methylation occurs almost
exclusively at CpG dinucleotides, which are enriched at
CpG islands, often are located at 5’-/promoter regions of
functional genes [10]. Cytosine methylation may result in
transcriptional repression either by interfering with tran-
scription factor binding or by inducing a repressive chro-
matin structure [11]. Apoptotic pathways are targets for
such “epigenetic” silencing, and several apoptosis-linked
genes that are regulated directly or indirectly by methyla-
tion have been described [12].
In this study, we first probed whether KLK1 excretion is
altered in human AKI, and if so what mechanisms (endo-
crine or epigenetic) might be driving the change. Since
kidney repair after injury may recapitulate normal mor-
phogenesis, we hypothesized that urinary kallikrein levels
would be associated with severity of AKI and with epige-
netic changes in the renal kallikrein-1 (KLK1) promoter.
We considered that changes in kallikrein excretion or the
KLK1 promoter might predict renal functional recovery
and thus serve as biomarkers of recovery from AKI,
thereby facilitating timely diagnosis and treatment. We
therefore examined patients with AKI for urinary expres-
sion of KLK1 enzymatic activity, as well as genomic DNA




Cases were ascertained from a single center prospective
non-concurrent observational cohort of inpatients who
were identified as having suffered acute kidney injury
(AKI) during a hospital admission. The institutional review
board of the University of California, San Diego (UCSD)
reviewed and approved the study as well as the consent
document. Primary providers referred potentially eligible
patients to investigators and study coordinators. Patients
were eligible for enrollment if they were greater than 18
years of age and met the serum creatinine criteria for
acute kidney injury as set out by the Acute Kidney Injury
Network (AKIN) [13]: an abrupt rise by ≥0.3 mg/dl within
a 48-hour period. Patients were excluded if they received
chronic renal replacement therapy (hemodialysis or perito-
neal dialysis) within the 6 months prior to admission; had
ever been in receipt of a kidney transplant; pregnant or
breast feeding; currently incarcerated or otherwise institu-
tionalized (nursing home, rehabilitation); were placed
under hospice/comfort care; or did not have reasonable
expectation of survival past the present hospitalization. If
eligible, the patient or authorized representative was pre-
sented the study and consent for participation was
obtained. All relevant patient data were derived from the
electronic and paper medical records, as well as direct
interview of the patient or surrogate. Basic demographic
information and co-morbid conditions were recorded on
enrollment. Etiology of AKI was determined by chart
review of provider diagnosis, and verification by study per-
sonnel; diagnosis followed the categories set by the Project
to Improve Care of Acute Renal Disease (PICARD) study
investigators [1]. Daily assessment included medication
review, physical exam (as recorded in medical record or
assessed by study personnel when missing), vital signs,
intake and output, and labs. Clinical data elements were
collected daily and the need for and utilization pattern of
renal replacement therapy was also monitored and
recorded. Blood and urine samples were collected at time
of entry, daily for 7 days maximum, and at hospital
discharge. Twenty-four hour urine collections were per-
formed at study entry and hospital discharge for creati-
nine/urea clearance (in approximation of glomerular
filtration rate - GFR) as well as urinary kallikrein activity.
One sample of whole blood was collected for genomic
DNA preparation (and genetic analysis of the KLK1 locus)
at the time of study entry. At the time of discharge,
follow-up appointments with either the primary care
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physician or a nephrologist (not all patients were seen by a
nephrologist during the hospitalization), extent of renal
recovery, and dialysis dependence (if needed during hospi-
talization) were ascertained. Recovery: pre-defined study
endpoints were 12 months of follow-up, start of mainte-
nance hemodialysis or peritoneal dialysis, receipt of a kid-
ney transplant, or death; recovery of renal function was
the primary outcome, defined as a return to within 10% of
baseline eGFR or lowest eGFR prior to AKI event. Recov-
ery was assessed at 6 months of follow-up.
Healthy (non-hospital) controls
In addition, we obtained data for a control group of 38
healthy adult subjects. Each healthy control was selected
from only one member from each of 38 twin pair sets.
Twin pairs were recruited by a population-based twin reg-
istry in southern California [14], and by newspaper adver-
tisement. These twins are of European, African-American,
and Asian biogeographic ancestry. Ethnicity was estab-
lished by self-identification. Self-reported zygosity was
confirmed by extensive SNP genotyping. There was no
clinical evidence for kidney disease or any other cardiovas-
cular disorder in any of the controls. Untimed (spot) urine
collections were performed, and one sample of EDTA-
anticoagulated whole blood was collected for genetic
analysis of the KLK1 locus at the time of study entry.
Replication: Incipient (early) AKI cases in an intensive care
unit (ICU), with ICU control subjects
An additional sample of controls was ascertained for
replication of findings, in an ICU setting. In brief, the
replication sample consisted of n = 44 subjects (“ICU
controls”) who did not develop AKI during a 7-day
observation period after hospital ICU admission, as well
as n = 11 subjects (ICU cases) who did develop AKI, as
defined above. Patients were screened at ICU admission
for potential study participation at three academic medi-
cal centers (University of California San Diego, Univer-
sity of Alabama, and Université de Montréal) between
July 2006 and December 2008. Patients were eligible for
enrollment if they were age 18 or older and had a life
expectancy of at least 48 hours. Controls were excluded
if they had AKI according to the AKIN criteria [13],
were admitted to the ICU > 48 hours prior to screening,
transferred from another ICU, had a serum creatinine >
2 mg/dl ≤ 3 days before ICU admission, were prisoners,
received dialysis within the 12 months prior to admis-
sion, had a functioning kidney transplant, were on antic-
oagulants or warfarin within the last 7 days, suffered
from decompensated cirrhosis, had CKD stage 5, were
anemic (hemoglobin < 9.0 mg/dl or hematocrit < 27%),
or were already enrolled in another research project.
The study was approved by the Institutional Review
Boards at each institution, and written informed consent
was obtained from all participants or their health care
surrogates. Following informed consent, data on past
medical history were collected once, and clinical, labora-
tory and process-of-care elements were collected daily.
Each institution’s local laboratory measured serum crea-
tinine values. AKI was defined as an increase in serum
creatinine level of more than 0.3 mg/dL or more than
50% from a reference creatinine within 48 hours (AKIN
criteria)[13]. Patients without AKI within the first 4 days
had continued blood and urine samples twice daily, for
a total study observation period of 7 days.
Biochemical assays
Urine was assayed for kallikrein by an alkaline amidoly-
tic activity assay as previously described (4), using the
chromogenic substrate S-2266: [D] Val-Leu-Arg-parani-
troanilide (Kabi Pharmacia; Franklin, OH, USA) [5,15].
The activity of kallikrein per liter of urine (units per
liter, U/L) is calculated from the formula: U/L =
(9.55·A), where A = absorbance, after a 30-min assay
incubation of the paranitroanilide product in a spectro-
photometer at 405 nm [5,15]. Inclusion or exclusion of
the kallikrein inhibitor aprotinin (Trasylol, Miles Inc.,
West Haven, CT, USA) indicated that a fraction of
human urinary S-2266 amidolytic activity in the absence
of aprotinin was non-kallikrein (likely urokinase) [15];
thus, aprotinin (20 kallikrein inhibitory U/mL) was sys-
tematically included in the assay blank, to assure specifi-
city for kallikrein measurement. The inter-assay
coefficient of variation was 18.1%, and activities from
n = 20 samples measured on two separate occasions
correlated highly (Spearman R = 0.92, P< 0.01). In n =
87 subjects, activity correlated (Spearman R = 0.82, P<
0.0001) when results were compared for kallikrein
excretion normalized to time versus creatinine excre-
tion. Specificity of the S-2266 amidolytic assay for
glandular (KLK1, including renal, pancreas, and salivary)
kallikrein activity in urine arises from two features: first,
the substrate S-2266 is cleaved only by a particular sub-
set of serine proteases, including KLK1; and second, the
inclusion of aprotinin in the assay blank, which specifi-
cally inhibits serine proteases including KLK1; nonethe-
less, only an immunoassay specific for lysyl-bradykinin
(the kinin product of KLK1) generation could provide
absolute assurance of specificity for KLK1.
Clinical chemistries (serum or urine, electrolytes or
creatinine) were measured by spectrophotometric autoa-
nalyzer. Urine aldosterone concentration was deter-
mined by enzyme immunoassay (Alpco Diagnostics,
Salem, NH, USA). Urine catecholamine concentration
was determined by commercial ELISA kit (Labor Diag-
nostika Nord GmBH & Co. KG, Nordhorn, Germany).
Urine values were normalized to creatinine concentra-
tion in the same sample.
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DNA extraction and bisulfite treatment of CpG sites
A sample of EDTA-anticoagulated whole blood was
obtained from participants and stored at -70°C prior to
DNA extraction. Timed and spot urine samples were
obtained and frozen at -70°C before assay. Blood DNA
was prepared from blood leukocytes with a commercial
kit (QIAamp® DNA Mini Kit; Qiagen, USA). Urine
DNA was prepared from the urine pellet with spun col-
umns (urine DNA isolation kit; Norgen, Canada). Both
DNAs were subjected to sodium metabisulfite
(Na2S2O5) treatment (Imprint™ DNA Modification Kit;
Sigma, USA), and then eluted in 20 μL elution buffer.
Bisulfite converts cytosine residues to uracil, but leaves
5-methylcytosine residues unaffected.
KLK1 promoter CpG methylation analysis
Pyrosequencing for allele discrimination (Pyrosequencing;
Qiagen, USA) provides real-time extension-based DNA
analysis that can evaluate multiple CpG sites [16]. CpG
methylation analysis at the 5’/upstream/proximal promo-
ter region of human kallikrein serine protease 1 (KLK1)
gene was performed. The KLK1 gene was analyzed by a
single PCR amplicon spanning 4 CpGs in a 263 bp region,
with two biotinylated sequencing (extension) primers
(Figure 1). The consecutive 4 CpGs were located -203 to
-135 bp from the transcription initiation site: sequentially
at -203, -196, -154, and -135 bp (Figure 1).
As a control, global CpG methylation analysis was com-
pleted using PyroMark LINE-1 reagents (Pyrosequencing;
Qiagen, USA). We thus determined the methylation status
of three CpG sites in LINE-1 repetitive (LTR-like) ele-
ments, wherein methylation levels of CpG sites represent
global methylation status across the genome, because of
the repetitive nature of LINE-1 elements [17,18].
PCR amplification was performed using 10X PCR buf-
fer, 3.0 mM MgCl2, 200 μM of each dNTP, 0.2 μM each
of forward and reverse primers, HotStar DNA polymer-
ase (Qiagen, USA) 1.25 U, and ~10 ng of bisulfite-
converted DNA per 50 μl reaction. PCR cycling condi-
tions were: 94°C 15 min; 45 cycles of 94°C 30 s, 56°C
30 s, 72°C 30 s; 72°C 5 min; and then products were
held at 4°C. The PCR was performed with one of the
PCR primers biotinylated to convert the PCR product to
single-stranded DNA template. PCR products (each
10 μl) were sequenced by Pyrosequencing PSQ96 HS
System (Pyrosequencing, Qiagen, USA). The methylation
status of each locus was analyzed individually as a T/C
SNP using Pyro-QCpG™ software (Pyrosequencing).
AKI case samples were evaluated at study entry (base-
line, time of diagnosis). After bisulfite modification and
PCR amplification, KLK1 blood DNA promoter methyla-
tion data from 13 AKI patients and 30 controls were
obtained. KLK1 urine DNA promoter methylation data
from 9 AKI and 22 controls were available. LINE-1 blood
DNA methylation data from 14 AKI patients and 32 con-
trols were available for evaluation. LINE-1 urine DNA
methylation data from 15 AKI patients and 32 controls
were obtained.
Statistical analyses
Results are expressed as the mean value ± one standard
error of the mean (SEM) for continuous variables. For
comparisons of two groups, unpaired two-sided t-tests
or one-way ANOVA (enabling adjustment for covariates
of age, sex, and ethnicity) were performed. Non-para-
metric Wilcoxon Rank Sum test was used to confirm
parametric tests in the face of relatively small sample
sizes. Proportions were evaluated by Fisher’s exact test
(2 × 2 tables) or chi-square test (3 × 2 tables). Statistical
analyses were performed in R2.10.1 <http://www.r-pro-
ject.org/ > or SPSS-17 (Statistical Package for the Social
Sciences; Chicago, IL, USA). A P value of < 0.05 was
Figure 1 Map of CpG sites studied in the human KLK1 proximal promoter. Letters highlighted in gray are the target regions
complementary to amplified PCR primers. The CpGs analyzed are numbered as Pos#1 - Pos#4 and colored yellow. Green underlined sequences
are target regions complementary to sequencing primers. Green highlighted A is the transcriptional initiation ("cap”) site. Sequences following
the transcription initiation site are colored pink.
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considered significant. Multiple linear regression was
performed with default criteria of entry (p < 0.05) and
exit (p > 0.10) from the multivariate regression model,
using stepwise or forward options. Recovery from AKI
was pre-defined as return (within 6 months follow-up)
to within 10% of baseline eGFR, or lowest eGFR prior to
AKI event.
Results
Renal KLK1 excretion and eGFR in the 4 subject groups:
AKI cases and controls
Demographic and anthropometric description of the
study samples is presented in Table 1. Baseline demo-
graphic characteristics (age, sex) were similar across
groups.
As compared to healthy/outpatient controls (Table 1,
Figure 2), ICU/inpatient controls displayed unaltered
eGFR, though a modest ~3.2-fold increase in urinary
KLK1 excretion. ICU subjects with incipient AKI had a
modest fall in eGFR (down ~38% compared to ICU con-
trols), coupled with a ~43% fall in KLK1 excretion.
However, subjects with established (more severe) AKI
exhibited a ~6.9-fold increase in KLK1 excretion (p =
2.09E-05), coupled with a further ~27% fall in eGFR
(p = 3.10E-10).
Established AKI: Clinical characteristics
We then turned our attention to clinical features (Table 2)
of the AKI subjects that might account for the KLK1 ele-
vation. In clinical laboratory findings at study enrollment
(entry), patients with AKI had significantly higher serum
creatinine (2.67 ± 0.43 vs. 0.9 ± 0.04 mg/dl; p < 0.001),
and fractional excretion of sodium (FeNa+; 1.7 ± 0.4 vs.
0.8 ± 0.06%; p = 0.05), than healthy controls, with lower
eGFR (44.4 ± 7.5 vs. 97.5 ± 3.6 ml/min; p = 0.0001).
At study enrollment, AKI patients had lower SBP (119.8
± 4.4 vs. 131.4 ± 1.7 mmHg; p = 0.02) and higher heart
rate (89.3 ± 3.6 vs. 68.0 ± 1.6 beats/min; p = 1.73E-05)
than healthy controls. Within the AKI group (n = 20),
acute kidney injury was attributed to ischemia in 7
patients, nephrotoxins in 4, sepsis in 1, and multifactorial
causes in 8 (Table 2); KLK1 excretion did not vary by AKI
causal group (ANOVA p = 0.83). Six patients had diabetes
mellitus, 10 had hypertension, 1 had coronary artery dis-
ease, 6 had chronic liver disease, 4 had chronic lung dis-
ease, 8 had chronic kidney disease (previous eGFR <
60 ml/min), 13 required admission to an ICU during hos-
pitalization, 5 required mechanical ventilation at enroll-
ment, and 5 had oliguria at enrollment. At study entry,
3 patients required infusion of vasopressors (2 norepi-
nephrine, 1 dopamine and epinephrine combination), and
3 took diuretics (2 furosemide, 1 thiazide). In the evalua-
tion of primary outcome, 17 patients attained recovery of
renal function (see Methods) at 6 months of follow-up
(Table 1).
Established AKI: Kallikrein, catecholamines, and
aldosterone
Here we probed potential hormonal mechanisms
whereby KLK1 excretion was elevated in established
AKI, focusing on such known KLK1 stimulators as cate-
cholamines [19] and aldosterone.
Urinary kallikrein enzymatic activity
From the 20 established AKI patients and 38 healthy con-
trols, urine was available for kallikrein measurement
(Table 3) in 18 patients and 37 controls. Unexpectedly,
established AKI subjects displayed substantially elevated
kallikrein excretion (Figure 2, Table 1), about ~10 times
higher than that of controls (activity: 6132.9 ± 2302 vs.
623.0 ± 88.2 mU/L, p < 0.001; urine kallikrein activity/
creatinine ratio: 6.74 ± 1.92 vs. 0.63 ± 0.08 U/gm, p <
0.001). To exclude the possibility that diuretic treatment
at study entry increased urinary kallikrein excretion [20],
we conducted statistical analysis again by exclusion of the
3 diuretic cases (Tables 1); urinary kallikrein excretion
remained significantly different between AKI and controls
(urine kallikrein/urine creatinine ratio: 7.14 ± 2.18 vs. 0.63
± 0.08 mU/mg; p = 0.001). We measured the urinary non-
kallikrein amidolytic activity (likely urokinase) by inclusion
or exclusion of the kallikrein inhibitor aprotinin. The per-
centage of kallikrein activity within total S-2266 amidolytic
activity was not different between AKI patients and con-
trols (78.0 ± 4.8% vs. 69.0 ± 2.4%; p = 0.072).
Since black and white subjects differ in reported KLK1
excretion [5,15], we evaluated the role of ethnicity in
our samples (Table 1). Although cases and controls each
included several biogeographic ancestries, KLK1 excre-
tion did not differ significantly in black versus white
cases (p = 0.26) or black versus white controls (p =
0.69), perhaps reflecting the relatively small sample
sizes. Disease analyses were adjusted for biogeographic
ancestry as a covariate.
Urinary aldosterone and catecholamine excretions
We measured urinary aldosterone, epinephrine and nore-
pinephrine excretions (Table 3), since these hormones
are known to increase urinary kallikrein. Established AKI
subjects exhibited substantially elevated epinephrine
excretion, ~2.7 times higher than that of healthy controls
(Table 3, Figure 3; 20.1 ± 2.4 vs. 7.48 ± 1.07 ng/mg creati-
nine; ANOVA p = 0.00016). Urinary kallikrein/epinephr-
ine ratio did not differ between groups (Table 3); parallel
elevations of KLK1 and epinephrine suggest that the epi-
nephrine excess in AKI may be sufficient to account for
the increased KLK1. To exclude the possibility that
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Table 1 Clinical characteristics of cases and controls: Established versus incipient AKI cases, and ICU versus healthy
controls
AKI Controls
P < 0.05 (*) Established Incipient (early, ICU) ICU Healthy
(non-hospital)
Characteristics n = 20 n = 11 n = 44 n = 38
Age, years * 48.8 ± 3.5 68.1 ± 3.8 52.9 ± 2.3 46.3 ± 1.5
Sex (male/female) 15/5 5/6 26/18 28/10
Ethnicity, n *
White 11 5 28 20
Black 3 4 8 6
Hispanic 5 0 7 6
Other 1 2 1 6
Lab findings at enrollment
sCr, mg/dl * 2.67 ± 0.43 1.29 ± 0.12 0.81 ± 0.05 0.9 ± 0.04
eGFR, ml/min * 44.4 ± 7.3 60.9 ± 5.7 98.2 ± 4.9 97.5 ± 3.5
uCr/sCr, ratio * 42.4 ± 7.2 83.3 ± 18.1 106.6 ± 18.3 119.6 ± 5.2
Urine kallikrein
(U/gm creatinine)
* 6.74 ± 1.92 1.17 ± 0.16 2.04 ± 0.47 0.63 ± 0.08
Vital signs at enrollment
Systolic BP, mmHg 0.08 119.8 ± 4.4 126.9 ± 8.7 124.3 ± 3.4 131.4 ± 1.7
Diastolic BP, mmHg * 70.7 ± 3.4 61.8 ± 5.1 68.6 ± 2.3 74.7 ± 1.5
Heart rate, beats/min * 89.3 ± 3.6 86.5 ± 7.4 81.3 ± 2.4 68.0 ± 1.6
Co-morbid conditions (Y/N)
Diabetes mellitus 6/14 6/5 12/32 0/38
Hypertension * 10/10 8/3 20/22 8/30
Coronary artery disease 1/19 4/7 10/34 0/38
Congestive heart failure * 0/20 3/8 4/40 0/38
Chronic liver disease * 6/14 0/11 4/40 0/38
Chronic lung disease * 4/16 3/8 7/37 0/38
Chronic kidney disease * 8/12 3/8 1/43 0/38
HIV positive 2/18 0/11 3/41 0/38
Malignancy 3/17 1/10 12/32 0/38
Smoker * 8/12 3/8 16/28 4/34
Primary treating service, n
Medical/Surgical 14/6 11/0 34/10 -
Other characteristics while hospitalized (Y/N)
ICU admission * 13/7 11/0 44/0 -
Ventilator at enrollment 5/15 3/8 13/31 -
Pressor infusions * 3/17 9/2 12/32 -
Norepinephrine * 2/18 8/3 11/33 -
Epinephrine + dopamine * 1/19 9/2 12/32 -
Diuretics at enrollment * 3/17 5/6 2/42 -
AKI outcomes
Required dialysis for AKI 3/17 1/10 - -
Recovery from AKI * 17/3 11/0 - -
Remained dialysis-
dependent at follow-up
1/19 0/11 - -
Final eGFR at follow-up 66.5 ± 8.0 76.6 ± 5.5 - -
eGFR Δ at follow-up +16.5 ± 2.2 +22.2 ± 5.4 - -
sCr Δ at follow-up 0.08 -1.0 ± 0.3 -0.25 ± 0.05 - -
ICU = intensive care unit, AKI = acute kidney injury, n = number of study subjects, BMI = body mass index, s = serum, u = urine, Cr = creatinine, FeNa+ =
fractional excretion of sodium, SBP = systolic blood pressure, DBP = diastolic blood pressure, HR = heart rate, bpm = beats per minute. Δ = change at discharge
(from initial value). *P values calculated with Fisher’s exact test for categorical variables and ANOVA (log-transformed and covariates adjusted: age, sex) for
continuous variables. *: Symbol indicates P ≤ 0.05 comparing across all available groups. Recovery of renal function was the primary outcome, defined as a return
to within 10% of baseline eGFR or lowest eGFR prior to AKI event. Plus-minus values are mean ± SEM.
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epinephrine infusion (in one case, Tables 1) increased
urinary excretion, in a subsequent analysis we excluded
that case, but urinary epinephrine remained different
between AKI and controls (19.99 ± 2.62 vs. 7.48 ± 1.07
ng/mg creatinine; ANOVA p = 0.001). Indeed, Figure 3
illustrates parallel elevations of renal kallikrein and epi-
nephrine excretion in the AKI group.
Urinary aldosterone excretion did not differ between
established AKI and healthy controls (Table 3) (9269.9
± 2652.31 vs. 12982.4 ± 2619.78 pg/mg creatinine;
ANOVA p = 0.65). Since urinary kallikrein/aldosterone
ratio was also elevated in AKI (Table 3), increments in
aldosterone could not explain the rise in KLK1 excretion
in AKI. Urinary norepinephrine excretion did not differ
in AKI (Table 3) (37.15 ± 8.14 vs. 26.85 ± 3.20 ng/mg
creatinine; ANOVA p = 0.16); nor did urine kallikrein/
norepinephrine excretion ratios.
Urine albumin excretion
Quantitative urine albumin excretion was evaluated in
established AKI cases and healthy controls. Albumin
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Likely pathogenic pathway
Figure 2 Urinary kallikrein activity in AKI: Cases versus controls. Results are shown for both KLK1 excretion and eGFR in 4 groups:
established AKI, incipient (early, ICU) AKI, ICU controls, and healthy (non-hospital) controls. Results (shown as mean ± 1 SEM) were analyzed by
ANOVA, factoring for age, sex and race.
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(mean, 1090 mg/gm), but kallikrein and albumin excre-
tions did not correlate (Pearson r = 0.006, p = 0.54), ren-
dering it unlikely that elevated kallikrein activity in AKI
arose simply from pathological excretion of plasma pro-
teases. In healthy controls, albumin excretion was 6.27 ±
0.39 mg/gm creatinine.
ICU controls: Urinary kallikrein activity and clinical findings
44 “ICU controls” were available to evaluate the specifi-
city of urinary kallikrein elevation in AKI. Table 1
shows demographic, laboratory and clinical findings of
these ICU controls. The kallikrein increment in AKI
persisted when studied with ICU controls (6.74 ± 1.92
vs. 2.04 ± 0.47 U/gm creatinine; p = 0.028), though kal-
likrein excretion was modestly elevated in ICU- com-
pared to healthy controls (2.04 ± 0.47 vs. 0.63 ± 0.08 U/
gm creatinine; p = 0.005).
Compared with established AKI, ICU controls had sig-
nificantly lower serum creatinine (0.81 ± 0.05 vs. 2.67 ±
0.43 mg/dl; p = 0.0005). Compared with healthy con-
trols, ICU controls were older (54.2 ± 2.2 vs. 46.3 ± 1.5
years; p = 0.005), with higher heart rate (81.3 ± 2.4 vs.
68.0 ± 1.6 bpm; p < 0.0001), but lower DBP (68.6 ± 2.3
vs. 74.7 ± 1.5 mmHg; p = 0.029). Even though not sig-
nificantly different, SBPs of ICU controls tended to be
lower than those in healthy controls (124.3 ± 3.4 vs.
131.4 ± 1.7 mmHg; p = 0.066). The ICU controls had
variable primary diseases (Table 1). 13 among them
required mechanical ventilation, while 12 required vaso-
pressor infusion during ICU admission (Table 1).
KLK1 promoter DNA CpG methylation patterns
KLK1 promoter CpG methylation (positions in Figure 1)
was studied in established AKI and healthy controls.
Promoter KLK1 CpG methylation (Figure 4) was higher
in blood than urine DNA (blood 66.38 ± 1.00 vs. urine
33.43 ± 4.67%; ANOVA p < 0.0001). Promoter KLK1
methylation in blood DNA was also higher in AKI than
Table 2 Mechanistic studies: Characteristics of the AKI study subjects versus healthy controls






Age, years 48.8 ± 3.5 46.3 ± 1.5 0.52






Weight, kg 91.2 ± 6.2 93.9 ± 3.7 0.293
BMI, kg/m2 31.1 ± 2.2 27.8 ± 1 0.177
Laboratory findings at enrollment
sCr, mg/dl 2.7 ± 0.47 0.9 ± 0.04 0.0007
eGFR, ml/min 44.4 ± 7.5 97.5 ± 3.6 <
0.0001
uNa+/uCr, mEq/gm 127.6 ± 22.5 125.4 ± 9.4 0.347
uCr/sCr, ratio 42.4 ± 7.2 119.6 ± 11.4 <
0.0001
FeNa+, % 1.7 ± 0.4 0.8 ± 0.1 0.05
Vital signs at enrollment
Systolic BP, mmHg 119.8 ± 4.4 131.4 ± 1.7 0.02
Diastolic BP, mmHg 70.7 ± 3.4 74.7 ± 1.5 0.3
Heart rate, beats/min 89.3 ± 3.6 68.0 ± 1.6 <
0.0001
Contributing causes to AKI, n (with urine KLK1 activity excretion, U/gm creatinine,
mean ± SEM)
0.83
Ischemia 7 (6.0 ± 3.7) - -
Nephrotoxins 4 (7.2 ± 3.9) - -
Septic 1 (4.6) - -
Multifactorial causes/other 8 (7.6 ± 2.9) - -
AKI = acute kidney injury, n = number of study subjects, BMI = body mass index, s = serum, u = urine, Cr = creatinine, FeNa+ = fractional excretion of sodium,
SBP = systolic blood pressure, DBP = diastolic blood pressure, HR = heart rate, bpm = beats per minute, ICU = intensive care unit. *P values were calculated with
Fisher’s exact test for categorical variables, and ANOVA (log-transformed, adjusted for covariates: age, sex) for continuous variables. Plus-minus values are mean ±
one SEM. Bold: p ≤ 0.05.
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Table 3 Mechanistic studies: Urinary biochemistries in established AKI cases versus healthy controls
AKI patients n available Healthy controls n available T-test P ANOVA P† Wilcoxon rank P
Urine kallikrein (U/gm creatinine) 6.74 ± 1.92 18 0.63 ± 0.08 37 0.0058 0.00029 0.0012
Urine aldosterone (pg/mg creatinine) 9269.9 ± 2652.31 16 12982.4 ± 2619.78 38 0.325 0.65 0.1282
Urine epinephrine (ng/mg creatinine) 20.1 ± 2.4 14 7.48 ± 1.07 32 1.11E-06 0.00016 1.79E-05
Urine norepinephrine, (ng/mg creatinine) 37.15 ± 8.14 14 26.85 ±
3.2
32 0.344 0.16 0.4424
Urine kallikrein/urine aldosterone ratio (mU/μg) 872.0 ± 277.5 15 160.5 ±
76.7
38 0.00027 8.45E-05 3.62E-05
Urine kallikrein/urine epinephrine ratio (mU/ng) 0.32 ± 0.13 13 0.18 ±
0.04
31 0.8465 0.8 0.899



















controls (70.32 ± 2.27 vs. 65.36 ± 1.05%; ANOVA p =
0.011), while promoter KLK1 methylation in urine DNA
trended to be higher in AKI than controls (40.95 ± 7.06
vs. 30.35 ± 5.88%; ANOVA p = 0.22; Figure 4).
Global CpG methylation, examined by LINE-1, was
high in both blood and urine, though even higher in
blood (blood 73.11 ± 0.38 vs. urine 69.37 ± 0.86%, p =
0.0002). LINE-1 CpG methylation in blood DNA was
similar between AKI and controls (71.71 ± 0.44 vs. 73.67
± 0.41%; ANOVA p = 0.08), as was LINE-1 methylation
in urine DNA (AKI 69.53 ± 1.54 vs. control 69.29 ±
1.05%; ANOVA p = 0.79) (Figure 4). In AKI blood DNA,
KLK1-specific methylation was similar to global LINE-1
methylation (70.32 ± 2.27 vs. 71.71 ± 0.44%; p = 0.56). In
controls, however, KLK1 CpG methylation in blood DNA
was significantly lower than global LINE-1 methylation
in blood DNA (65.36 ± 1.05 vs. 73.67 ± 0.41%; p <
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Figure 3 Coordinate effects of AKI on kallikrein and epinephrine excretion. Results (shown as mean ± 1 SEM) were analyzed by one-way
ANOVA, factoring for age, sex and race. The numbers studied for kallikrein are 18 established AKI patients and 37 healthy controls. The numbers
studied for epinephrine are 14 established AKI patients and 32 healthy controls.
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specific methylation in urine DNA was significantly lower
than global LINE-1 methylation in urine DNA
(AKI 40.95 ± 7.06 vs. 69.53 ± 1.54%; p = 0.003; controls
30.35 ± 5.88 vs. 69.29 ± 1.05%; p < 0.0001) (Figure 4).
Urine KLK1 promoter CpG methylation did not pre-
dict KLK1 activity excretion. However, in a multivariate
analysis, disease status jointly predicted both KLK1 pro-
moter methylation and enzyme activity excretion, with
higher values for each in cases (multivariate p = 0.004;
Figure 5. Since increased KLK1 promoter methylation
would be predicted to decrease gene expression, this
joint effect cannot explain (and indeed runs counter to)




Several previous lines of investigation link alterations in
KLK1 expression to AKI, in both experimental animals
and humans. A decrease in urinary kallikrein excretion
occurs in rodents with AKI after methemoglobin [21];
rats treated with aminoglycosides have dramatically
reduced levels of urinary kallikrein [6], and a transient
decrease in urinary kallikrein excretion occurs during
Significance (by ANOVA):
Blood versus urine KLK1
methylation: p<0.0001 
AKI versus control KLK1
methylation in blood DNA: 
p=0.011
Blood versus urine DNA LINE-1
methylation: p=0.0002




Figure 4 CpG methylation analyzed by bisulfite sequencing: Results at the KLK1 promoter, as well as a global control (LINE-1
repetitive elements), in genomic DNA from urine or blood (mononuclear cells). Results (shown as mean ± one SEM), from established AKI
cases or healthy controls, were analyzed by ANOVA, factoring for age, sex and race. LINE-1 reagents (Pyromark, Biotage) were used to analyze
the 3 CpG sites in LINE-1 repetitive elements, while the KLK1 gene was analyzed by a separate PCR covering 4 promoter CpGs. Promoter KLK1
specific methylation was substantially higher in blood than urine DNA (blood 66.38 ± 1.00 vs. urine 33.43 ± 4.67%; ANOVA p < 0.0001). Promoter
KLK1 methylation in blood DNA was higher in AKI than controls (AKI, 70.32 ± 2.27 vs. controls, 65.36 ± 1.05%; ANOVA p = 0.011). Promoter KLK1
methylation in urine DNA did not differ in AKI versus controls (AKI, 40.95 ± 7.06 vs. controls, 30.35 ± 5.88%; ANOVA p = 0.22). Global LINE-1
methylation was greater in both blood than urine DNA (blood 73.11 ± 0.38 vs. urine 69.37 ± 0.86%, p = 0.0002). LINE-1 methylation in blood
DNA did not differ in AKI and controls (AKI, 71.71 ± 0.44 vs. controls, 73.67 ± 0.41%; ANOVA p = 0.08). LINE-1 methylation in urine DNA did not
differ in cases/controls (AKI, 69.53 ± 1.54 vs. controls, 69.29 ± 1.05%; ANOVA p = 0.79).
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chromate-induced AKI in the rat [22]. Renal kallikrein
mRNA expression was specifically reduced in the post-
ischemic rodent kidney, with persistently altered expres-
sion even after functional recovery from ischemic acute
renal failure [23]. In humans, we reported previously
that urinary kallikrein excretion was diminished in acute
tubular necrosis (ATN) after renal transplantation [9].
Studies in rodents suggest beneficial effects of exogen-
ous KLK1 replacement in the setting of experimental
AKI. KLK1 gene transfer protected against aminoglyco-
side-induced nephropathy, with inhibition of apoptosis
and inflammation [7]. KLK1 replacement after gentami-
cin attenuated drug-induced renal dysfunction, cortical
damage, and apoptosis in the rat [8]. Furthermore, KLK1
reduced gentamicin-induced renal dysfunction and fibro-
sis, with decreased myofibroblast and collagen accumula-
tion [8]. These findings indicate that the renal kallikrein/
kinin system prevents and promotes recovery of amino-
glycoside-induced renal injury by inhibiting apoptosis,
inflammatory cell recruitment, and fibrotic lesions.
Thus, we expected that AKI patients would have
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Figure 5 AKI: Coordinate effects of disease on KLK1 promoter CpG methylation and KLK1 enzymatic activity excretion in urine. The
multivariate analysis compared established AKI cases with healthy controls.
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kallikrein originates in the kidney; further, we antici-
pated that kallikrein increments might be associated
with superior outcomes in AKI. Unexpectedly our estab-
lished AKI subjects displayed substantially elevated (by
as much as ~11-fold; ANOVA p = 0.00029; Figure 2;
Tables 1,3) kallikrein excretion.
Origin of increased KLK1 excretion in established AKI
Although previous reports of KLK1 excretion in AKI
indicated diminished excretion in both rodent models
[6,21,22] and AKI/ATN in the setting of human renal
transplantation [9], we noted a ~11-fold elevation of
KLK1 excretion in our established AKI subjects (Tables
1-3; Figure 2). Why might KLK1 excretion be elevated
in human AKI? Here we examined hormonal factors
known to increase KLK1 excretion: catecholamines and
aldosterone [5,19,20,24-26]. We found that an elevation
in epinephrine excretion paralleled that for kallikrein
(Figure 3), while norepinephrine and aldosterone excre-
tions were unchanged (Table 3). In experimental ani-
mals, kallikrein excretion is regulated by adrenergic
receptors, with stimulation by b-receptors and inhibition
by a-receptors [19]. While diuretics can also elevate kal-
likrein excretion [20,27], the KLK1 excretion increment
in AKI persisted after exclusion of the 3 subjects on
diuretics.
Why was epinephrine elevated in our AKI subjects?
AKI patients had lower systolic BP than controls (119.8 ±
4.4 vs. 131.4 ± 1.7 mmHg; p = 0.02) and higher heart rate
(89.3 ± 3.6 vs. 68.0 ± 1.6 bpm; p = 1.73E-05) (Table 2).
While the mechanism cannot be readily probed in the
setting of acute human illness, we suspect that that lower
BP in AKI may stimulate baroreceptors, with resulting
increase in endogenous production of epinephrine, and
consequently increased heart rate and kallikrein excre-
tion (Figure 6).
KLK1 epigenetics
Promoter KLK1 specific CpG methylation was higher in
blood than urine DNA (blood 66.38 ± 1.00 vs. urine
33.43 ± 4.67%; ANOVA p < 0.0001; Figure 4), consistent
with kidney-specific expression of the KLK1 gene, in
that renal kallikrein is synthesized in the distal tubule
and released into urine and peritubular interstitium [20],
and cytosine methylation results in transcriptional
repression either by interfering with transcription factor










Human AKI: Hypothetical schema for steps












Figure 6 Hypothetical schema integrating experimental findings in this study of KLK1 in AKI. This diagram is presented not as established
fact, but rather to generate hypotheses for further investigation. Endogenous factors may influence KLK1 synthesis and renal excretion: lower BP
in AKI may activate baroreceptors, thus increasing endogenous secretion of epinephrine, thereby increasing both heart rate and urinary kallikrein
excretion. KLK1 promoter genetic variants or CpG methylation can influence renal kallikrein production. Finally, exogenous factors such as
adrenergic pressor infusions or diuretic treatment can also increase renal kallikrein production; indeed, since a subset of our AKI cases received
such treatments (Table 1), we cannot exclude this possibility.
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KLK1 promoter methylation in blood DNA was higher
in AKI than controls (70.32 ± 2.27 vs. 65.36 ± 1.05%; p =
0.011), and there was also a trend towards higher urine
KLK1 methylation in AKI than controls, but the difference
was not significant (40.95 ± 7.06 vs. 30.35 ± 5.88%; p =
0.22). While a multivariate analysis indicated a joint effect
of AKI on both KLK1 excretion and urine KLK1 CpG
methylation (Figure 5), elevated KLK1 methylation would
be predicted to decrease KLK1 excretion in AKI, as occurs
in early/incipient AKI (Figure 2). Increased KLK1 excre-
tion in later/established AKI (Figure 2) thus highlights the
influence of epinephrine (Figure 3) to elevate KLK1, even
in the face of opposing epigenetic influence.
LINE-1 methylation results enabled comparisons of
KLK1 to global genomic patterns of CpG methylation
[18]. In AKI blood DNA, KLK1-specific methylation was
similar to global LINE-1 methylation (70.32 ± 2.27 vs.
71.71 ± 0.44%; p = 0.56). In control blood DNA, however,
KLK1-specific methylation was lower than global LINE-1
methylation (65.36 ± 1.05 vs. 73.67 ± 0.41%; p < 0.0001)
(Figure 4).
We investigated the 4 most proximal consecutive CpG
sites in KLK1 promoter (Figure 1). This proximal promo-
ter region is unusually polymorphic, containing a poly-
guanine length polymorphism coupled with multiple base-
substitution variants that constitute at least ten different
alleles or haplotypes [28]. Functional/transfection analysis
of several alleles in this region suggests that different var-
iants lead to alterations in expression of the KLK1 gene
[29]. Since genetic variation may contribute to AKI sus-
ceptibility [30], this hypothesis warrants future studies of
KLK1 promoter variants in larger cohorts, assessing the
effects of such variants on both susceptibility and recovery
in AKI, since exogenous KLK1 does exert protective effects
against aminoglycoside-induced AKI [7,8].
It should be noted that the sources of DNA for these
epigenetic studies in blood and urine are likely to be het-
erogeneous - blood DNA could emerge from any leuko-
cyte subpopulation, while DNA in urine can emerge from
cell types other than renal. Nor have we established
whether the promoter CpG methylation events we
observed have functional consequences for transcription.
Advantages and limitations of this study
Our conclusions are derived from analysis of four subject
groups (Figure 2): two degrees of AKI (established versus
incipient/early), and two kinds of controls (ICU versus
healthy/non-hospital). Furthermore, we were able to probe
clinical and biochemical characteristics of cases and con-
trols to identify elevated epinephrine as a likely driver of
increased KLK1 excretion (Figure 3, Table 3). While we
were able to evaluate epigenetic factors in control of KLK1
excretion in the form of promoter CpG methylation
(Figures 1, 4), we did not study other epigenetic mechan-
isms, such as histone modifications, nor could we probe
gene expression more directly by evaluating transcript
abundance in tissue, since biopsies would have been
hazardous. Furthermore, the established AKI cases were
ascertained at a later time point than either AKI cases or
controls in the ICU cohorts. Finally, the results would ben-
efit from replication, given the numbers of subjects studied
(Figure 2, Table 1), as well as evaluation of additional
mediators of AKI risk and repair.
Conclusions
In conclusion, human patients with established AKI display
an unexpected increase in urinary KLK1 enzymatic activity
excretion (Figure 2); the effect is reproducible across con-
trol groups, and seems to be driven by epinephrine excess
in the setting of hemodynamic instability (Figures 3, 6).
AKI and controls differed in KLK1 promoter CpG methy-
lation in blood DNA (AKI > controls), and KLK1 CpG
methylation differed systematically from global control
(LINE-1 element) methylation, suggesting a potential role
of epigenetic factors in AKI susceptibility (Figure 4).
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